DOCSLIB.ORG

FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma Published OnlineFirst October 14, 2016; DOI: 10.1158/1078-0432.CCR-16-1874 Cancer Therapy: Clinical Clinical Cancer Research FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma Amy K. Erbe1,WeiWang1, Jacob Goldberg1, Mikayla Gallenberger1, KyungMann Kim2, Lakeesha Carmichael2,DustinHess1,EneidaA.Mendonca2,3, Yiqiang Song2, Jacquelyn A. Hank1,Su-ChunCheng4, Sabina Signoretti5, Michael Atkins6,7, Alexander Carlson8,JamesW.Mier6,8, David J. Panka8, David F. McDermott6,8,and Paul M. Sondel1,3 Abstract Purpose: Fc-gamma receptors (FCGRs) are expressed on Results: When higher-affinity genotypes for FCGR2A, FCGR3A, immune cells, bind to antibodies, and trigger antibody-induced and FCGR2C were considered together, they were associated with cell-mediated antitumor responses when tumor-reactive antibo- significantly increased tumor shrinkage and prolonged survival in dies are present. The affinity of the FCGR/antibody interaction is response to HD-IL2. variable and dependent upon FCGR polymorphisms. Prior stud- Conclusions: Although associations of higher-affinity FCGR ies of patients with cancer treated with immunotherapy indicate genotype with clinical outcome have been demonstrated that FCGR polymorphisms can influence antitumor response for with mAb therapy and with idiotype vaccines, to our knowl- certain immunotherapies that act via therapeutically administered edge,thisisthefirst study to show associations of FCGR mAbs or via endogenous tumor-reactive antibodies induced from genotypes with outcome following HD-IL2 treatment. We tumor antigen vaccines. The previously published "SELECT" trial hypothesize that endogenous antitumor antibodies may of high-dose aldesleukin (HD-IL2) for metastatic renal cell carci- engage immune cells through their FCGRs, and HD-IL2 may noma resulted in an objective response rate of 25%. We evaluated enhance antibody-induced tumor destruction, or antibody- the patients in this SELECT trial to determine whether higher- enhanced tumor antigen presentation, via augmented acti- affinity FCGR polymorphisms are associated with outcome. vation of innate or adaptive immune responses; this FCGR- Experimental Design: SNPs in FCGR2A, FCGR3A, and mediated immune activity would be augmented through FCGR2C were analyzed, individually and in combination, for immunologically favorable FCGRs. Clin Cancer Res; 1–10. associations between genotype and clinical outcome. Ó2016 AACR. Introduction "SELECT" clinical trial of high-dose IL2 (HD-IL2) to prospectively determine whether certain clinical and pathologic criteria [the Patients with metastatic renal cell carcinoma (mRCC) show a type of mRCC tumor (clear cell vs. non–clear cell), carbonic 14% to 22% response to the standard high-dose regimen of anhydrase 9 (CA-9) tumor staining and CA-9 polymorphism aldesleukin (IL2). On the basis of retrospective analyses of status, programmed death ligand 1 (PD-L1) tumor staining, patients with mRCC that had been treated with IL2, potential B7-H3 tumor staining, as well as other criteria] are associated biomarkers that may be useful for response predictions were with response to IL2. As noted in the clinical report, correlations assessed in the "SELECT" clinical trial conducted by the Cytokine were observed between the immune cell modulatory ligand, Working Group. Patients with mRCC were entered into the PD-L1, and immune response, and the study produced a response rate of 25% (1). In an effort to further identify genetic markers that might associate with efficacy of the HD-IL2 treatment for patients 1 Department of Human Oncology, University of Wisconsin, Madison, Wisconsin. with mRCC, and potentially identify immunologic mechanisms 2Department of Biostatistics and Medical Informatics, University of Wisconsin, 3 involved in the response, we sought to identify genotypic factors Madison, Wisconsin. Department of Pediatrics, University of Wisconsin, Madi- fl son, Wisconsin. 4Department of Biostatistics, Dana Farber Cancer Institute, that may in uence the immune activity of HD-IL2 therapy. In this Boston, Massachusetts. 5Department of Pathology, Brigham and Women's study, we genotyped SNPs found in certain activating Fc-gamma Hospital, Boston, Massachusetts. 6The Cytokine Working Group. 7Department receptor (FCGR) genes (FCGR2A, FCGR3A, and FCGR2C). of Medicine, Georgetown University, Washington DC. 8Division of Hematology/ Variably expressed on immune cells, FCGRs bind the Fc frag- Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts. ment of IgG antibodies (2–4). Upon engagement and cross- Note: Supplementary data for this article are available at Clinical Cancer linking, activating FCGRs transmit signaling within the immune Research Online (http://clincancerres.aacrjournals.org/). cell and initiate immune activation (5–7). FCGR2A (expressed on Corresponding Author: Paul M. Sondel, University of Wisconsin School of dendritic cells, macrophages, monocytes, neutrophils, and eosi- Medicine and Public Health, 1111 Highland Avenue, 4159 WIMR, Madison, WI nophils), FCGR3A [expressed on natural killer (NK) cells and 53705. Phone: 608-263-9069; Fax: 608-263-4226; E-mail: macrophages], and FCGR2C (also expressed on NK cells) are all [email protected] activating FCGRs (4, 8). The SNPs found in both FCGR2A and doi: 10.1158/1078-0432.CCR-16-1874 FCGR3A genes convey differential binding affinities for the Fc Ó2016 American Association for Cancer Research. portion of antibody. The FCGR2A SNP encodes amino acids of www.aacrjournals.org OF1 Downloaded from clincancerres.aacrjournals.org on October 2, 2021. © 2016 American Association for Cancer Research. Published OnlineFirst October 14, 2016; DOI: 10.1158/1078-0432.CCR-16-1874 Erbe et al. Translational Relevance Materials and Methods DNA Associations with clinical outcome were found in this study A total of 106 patients from the SELECT trial had DNA available in individuals that have a "favorable" FCGR genotype (higher- for genotyping, along with clinical data for correlative analyses. affinity alleles of FCGR2A and FCGR3A with the expression of DNA was isolated from peripheral blood mononuclear cells FCGR2C), suggesting that greater functionality of FCGRs plays following the manufacturer's protocol of the DNeasy Blood and a role in the antitumor activity of high-dose IL2 for patients Tissue Kit (Qiagen). DNA was kept at 4C during the time of with metastatic renal cell cancer (mRCC). The data presented analyses, and later was transferred to À80C for long-term storage in this report suggest that FCGRs may play a role in the in vivo after completion of the analyses. antitumor effect seen in patients with mRCC receiving high- fi dose IL2. These ndings raise important hypotheses for future Genotyping research that may focus on the potential role of endogenous All SNP genotyping was performed on a StepOnePlus quanti- antitumor antibody and indicate that future work should be tative PCR machine (ABI/Life Technologies). The FCGR2A SNP pursued to test whether the combined analyses of FCGR3A/ was determined using TaqMan primer/probes available from ABI/ 2A/2C genotypes may become a useful biomarker for pro- Life Technologies and used as per the manufacturer's protocol. For spective clinical planning and retrospective outcome analyses both FCGR3A and FCGR2C, Rnase H primers and probes for each for other clinical trials of cancer immunotherapy that may gene were developed in our laboratory to allow for specific involve NK cells or other FCGR-bearing immune cells. amplification of each gene. For genotyping the FCGR3A SNP, Rnase H primers were developed to specifically amplify FCGR3A while not coamplifying FCGR3B. These primers were paired with specific probes to determine the SNP (31). For genotyping the either histidine (H) or arginine (R) at position 131 of the FCGR2A FCGR2C-C/T SNP, Rnase H primers were developed to specifically protein (FCGR2A-H131R, rs1801274), and the FCGR3A SNP amplify this gene while not coamplifying FCGR2B. Primers and encodes either valine (V) or phenylaline (F) at amino acid 158 probes for both FCGR3A and FCGR2C were designed through of FCGR3A (FCGR3A-V158R, rs396991; refs. 9–12). The Integrated DNA Technologies (IDTDNA). Specific method details FCGR2A-H and FCGR3A-V receptors each have higher binding can be found in Erbe AK and colleagues, 2016 (31). Genotyping affinities to human IgG than do the FCGR2A-R and FCGR3A-F was conducted in a blinded manner, where those individuals that receptors, respectively (2, 4, 11). This stronger binding affinity determined the genotype of the patients did not have access to the results in more potent in vitro antibody-dependent cell-mediated clinical outcome data. Genotypes were verified for Hardy–Wein- cytotoxicity (ADCC) and tumor cell death (13, 14). In some berg equilibrium agreement (32); specific genotype results can be clinical trials involving various chimeric or humanized mAbs found in Supplementary Table S1. specific for head and neck, colorectal, or B-cell malignancies, both FCGR2A-H and FCGR3A-V SNPs are associated with improved Clinical data – clinical response (13 16). Similarly, in a trial of an idiotypic The clinical results of the SELECT trial have been published (1). vaccine for B-cell lymphoma, designed to induce endogenous As noted in the clinical report, patients received 600,000 IU/kg/ anti-idiotypic antibody, better outcome was seen for patients with dose of IL2 (Prometheus Laboratories Inc., San Diego, CA) IV every fi the higher-af nity FCGR2A-H and FCGR3A-V SNPs (16). Alter- 8 hours for 5
Load more

Recommended publications
  • Polymorphisms in FCGR2A (131H/R) and FCGR2B (232I/T) Are Associated with the Development of Inhibitors in Chinese Hemophilia a Patients
    Polymorphisms in FCGR2A (131H/R) and FCGR2B (232I/T) are associated with the development of inhibitors in Chinese hemophilia A patients Hong Qu ( [email protected] ) PanYu Central Hospital https://orcid.org/0000-0003-0728-2744 Yongfang Chen Guangzhou Panyu Central Hospital Wenjing Zeng Guangzhou Panyu Central Hospital Xiaohua Huang Guangzhou Panyu Central Hospital Shuqin Cheng Guangzhou Panyu Central Hospital Primary research Keywords: Hemophilia A, FCGR2A, FCGR2B, FVIII inhibitors, polymorphisms Posted Date: June 15th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-35124/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/9 Abstract Background: Present study was to explore the association between gene polymorphisms in Fc gamma receptor IIa (FCGR2A) and Iib (FCGR2B) and factor VIII (FVIII) inhibitor development in patients with hemophili A (HA) in a Chinese Han population. Methods: FCGR2A (131H/R) and FCGR2B (232I/T) polymorphsims were genotyped using PCR and direct sequencing method in 108 HA patients, including 23 cases with inhibitors and 85 without inhibitors. Chi- square (c2) test was applied to compare the genotype and allele frequencies between two groups. Odds ratio (OR) and 95% condence interval (95%CI) were calculated to indicate the relative susceptibility of HA. Results: FCGR2A 131RH genotype frequency had a signicantly increased trend in inhibitor group compared with the non-inhibitor group, suggesting a momentous role of 131H/R polymorphism for inhibitor development in HA patients. Individuals carrying 131RH genotype showed higher risk to be attacked by the inhibitor development in HA patients (OR=4.929; 95%CI=1.029-23.605).
    [Show full text]
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • The Role of Genetic Variants in FCGR2A on the Risk of Rheumatoid Arthritis in the Han Chinese Population
    The role of genetic variants in FCGR2A on the risk of rheumatoid arthritis in the Han Chinese population Yonghui Yang Clinical laboratory,Xi'an 630 hospital Linna Peng Xizang Minzu University Chunjuan He Xizang Minzu University Shishi Xing Xizang Minzu University Dandan Li Xizang Minzu University Tianbo Jin Xizang Minzu University Li Wang ( [email protected] ) Xizang Minzu University Research Keywords: Rheumatoid arthritis (RA), single nucleotide polymorphisms (SNPs), FCGR2A Posted Date: September 2nd, 2020 DOI: https://doi.org/10.21203/rs.3.rs-63617/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/21 Abstract Background: Rheumatoid arthritis (RA) is the most common inammatory arthritis and is characterized by irreversible joint damage and deformities, which is largely caused by genetic factors. The aim of this study was to explore the role of FCGR2A polymorphisms with the susceptibility to RA in the Han Chinese cohort. Methods: We enrolled 506 RA patients and 509 healthy controls, with four single nucleotide polymorphisms (SNPs) successfully genotyped using Agena MassARRAY. Genetic models, haplotype analyses were applied to assess the association between FCGR2A polymorphisms and RA. And we evaluated the relative risk by odds ratios (ORs) and 95% condence intervals (95% CIs) using logistic regression analysis. Results: The results revealed that FCGR2A rs6668534 was signicantly related to an increased risk of RA in the overall (OR = 1.24, 95%CI = 1.04 – 1.48, p = 0.014). There was no any association found between the polymorphisms and RA risk at age > 54 years, while the two (rs6671847 and rs1801274) of the four SNPs possibly contributed to the susceptibility to RA at age ≤ 54 years.
    [Show full text]
  • The Platelet Fc Receptor, Fcγ
    Jianlin Qiao The platelet Fc receptor, FccRIIa Mohammad Al-Tamimi Ross I. Baker Robert K. Andrews Elizabeth E. Gardiner Authors’ addresses Summary: Human platelets express FccRIIa, the low-affinity receptor Jianlin Qiao1, Mohammad Al-Tamimi2, Ross I. Baker3, Robert K. for the constant fragment (Fc) of immunoglobulin (Ig) G that is also Andrews1, Elizabeth E. Gardiner1 found on neutrophils, monocytes, and macrophages. Engagement of 1The Australian Centre for Blood Diseases, Monash this receptor on platelets by immune complexes triggers intracellular University, Melbourne, VIC, Australia. signaling events that lead to platelet activation and aggregation. Impor- 2Department of Basic Medical Sciences, Hashemite tantly these events occur in vivo, particularly in response to pathological University, Zarqa, Jordan. immune complexes, and engagement of this receptor on platelets has 3Western Australian Centre for Thrombosis and been causally linked to disease pathology. In this review, we will high- Haemostasis, Murdoch University, Perth, WA, Australia. light some of the key features of this receptor in the context of the pla- telet surface, and examine the functions of platelet FccRIIa in normal Correspondence to: hemostasis and in response to injury and infection. This review will Elizabeth Gardiner also highlight pathological consequences of engagement of this recep- Australian Centre for Blood Diseases tor in platelet-based autoimmune disorders. Finally, we present some Monash University new data investigating whether levels of the extracellular
    [Show full text]
  • CD226 T Cells Expressing the Receptors TIGIT and Divergent Phenotypes of Human Regulatory
    The Journal of Immunology Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226 Christopher A. Fuhrman,*,1 Wen-I Yeh,*,1 Howard R. Seay,* Priya Saikumar Lakshmi,* Gaurav Chopra,† Lin Zhang,* Daniel J. Perry,* Stephanie A. McClymont,† Mahesh Yadav,† Maria-Cecilia Lopez,‡ Henry V. Baker,‡ Ying Zhang,x Yizheng Li,{ Maryann Whitley,{ David von Schack,x Mark A. Atkinson,* Jeffrey A. Bluestone,‡ and Todd M. Brusko* Regulatory T cells (Tregs) play a central role in counteracting inflammation and autoimmunity. A more complete understanding of cellular heterogeneity and the potential for lineage plasticity in human Treg subsets may identify markers of disease pathogenesis and facilitate the development of optimized cellular therapeutics. To better elucidate human Treg subsets, we conducted direct transcriptional profiling of CD4+FOXP3+Helios+ thymic-derived Tregs and CD4+FOXP3+Helios2 T cells, followed by comparison with CD4+FOXP32Helios2 T conventional cells. These analyses revealed that the coinhibitory receptor T cell Ig and ITIM domain (TIGIT) was highly expressed on thymic-derived Tregs. TIGIT and the costimulatory factor CD226 bind the common ligand CD155. Thus, we analyzed the cellular distribution and suppressive activity of isolated subsets of CD4+CD25+CD127lo/2 T cells expressing CD226 and/or TIGIT. We observed TIGIT is highly expressed and upregulated on Tregs after activation and in vitro expansion, and is associated with lineage stability and suppressive capacity. Conversely, the CD226+TIGIT2 population was associated with reduced Treg purity and suppressive capacity after expansion, along with a marked increase in IL-10 and effector cytokine production. These studies provide additional markers to delineate functionally distinct Treg subsets that may help direct cellular therapies and provide important phenotypic markers for assessing the role of Tregs in health and disease.
    [Show full text]
  • Associations Between FCGR3A Polymorphisms and Susceptibility to Rheumatoid Arthritis: a Metaanalysis YOUNG HO LEE, JONG DAE JI, and GWAN GYU SONG
    Associations Between FCGR3A Polymorphisms and Susceptibility to Rheumatoid Arthritis: A Metaanalysis YOUNG HO LEE, JONG DAE JI, and GWAN GYU SONG ABSTRACT. Objective. To investigate whether the Fcγ receptor (FCGR) polymorphism confers susceptibility to rheumatoid arthritis (RA). Methods. We conducted metaanalyses on the associations between FCGR polymorphisms and RA susceptibility as determined using (1) allele contrast, (2) recessive models, (3) dominant models, and (4) contrast of homozygotes, using fixed or random effects models. Results. A total of 10 separate comparisons were considered, which comprised 6 European and 4 Asian population samples. Metaanalysis of FCGR3A polymorphism revealed a significant associa- tion between the VV genotype and the risk of developing RA relative to the VF+FF genotype (OR 1.256, 95% CI 1.045–1.510, p = 0.015), with no evidence of between-study heterogeneity (p = 0.167). In subjects of European descent, a stronger association was observed between the VV geno- type and RA than for the FF genotype (OR 1.374, 95% CI 1.101–1.714, p = 0.005). In Asians, no such association was found. Metaanalysis of the VV vs FF genotype revealed a significantly increased OR in Europeans (OR 1.399, 95% CI 1.107–1.769, p = 0.005), but not in Asians. No asso- ciation was found between RA and the FCGR2A and FCGR3B polymorphisms in all subjects and in European and Asian populations, except for the NA22 vs NA11 of FCGR3B in Europeans. Conclusion. No relation was found between the FCGR2A polymorphism and susceptibility to RA in Europeans or Asians. The FCGR3A polymorphism was found to be associated with RA in Europeans but not in Asians.
    [Show full text]
  • Single-Cell RNA Sequencing Demonstrates the Molecular and Cellular Reprogramming of Metastatic Lung Adenocarcinoma
    ARTICLE https://doi.org/10.1038/s41467-020-16164-1 OPEN Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma Nayoung Kim 1,2,3,13, Hong Kwan Kim4,13, Kyungjong Lee 5,13, Yourae Hong 1,6, Jong Ho Cho4, Jung Won Choi7, Jung-Il Lee7, Yeon-Lim Suh8,BoMiKu9, Hye Hyeon Eum 1,2,3, Soyean Choi 1, Yoon-La Choi6,10,11, Je-Gun Joung1, Woong-Yang Park 1,2,6, Hyun Ae Jung12, Jong-Mu Sun12, Se-Hoon Lee12, ✉ ✉ Jin Seok Ahn12, Keunchil Park12, Myung-Ju Ahn 12 & Hae-Ock Lee 1,2,3,6 1234567890():,; Advanced metastatic cancer poses utmost clinical challenges and may present molecular and cellular features distinct from an early-stage cancer. Herein, we present single-cell tran- scriptome profiling of metastatic lung adenocarcinoma, the most prevalent histological lung cancer type diagnosed at stage IV in over 40% of all cases. From 208,506 cells populating the normal tissues or early to metastatic stage cancer in 44 patients, we identify a cancer cell subtype deviating from the normal differentiation trajectory and dominating the metastatic stage. In all stages, the stromal and immune cell dynamics reveal ontological and functional changes that create a pro-tumoral and immunosuppressive microenvironment. Normal resident myeloid cell populations are gradually replaced with monocyte-derived macrophages and dendritic cells, along with T-cell exhaustion. This extensive single-cell analysis enhances our understanding of molecular and cellular dynamics in metastatic lung cancer and reveals potential diagnostic and therapeutic targets in cancer-microenvironment interactions. 1 Samsung Genome Institute, Samsung Medical Center, Seoul 06351, Korea.
    [Show full text]
  • Associations Between FCGR3A Polymorphisms and Susceptibility to Rheumatoid Arthritis: a Metaanalysis YOUNG HO LEE, JONG DAE JI, and GWAN GYU SONG
    Associations Between FCGR3A Polymorphisms and Susceptibility to Rheumatoid Arthritis: A Metaanalysis YOUNG HO LEE, JONG DAE JI, and GWAN GYU SONG ABSTRACT. Objective. To investigate whether the Fcγ receptor (FCGR) polymorphism confers susceptibility to rheumatoid arthritis (RA). Methods. We conducted metaanalyses on the associations between FCGR polymorphisms and RA susceptibility as determined using (1) allele contrast, (2) recessive models, (3) dominant models, and (4) contrast of homozygotes, using fixed or random effects models. Results. A total of 10 separate comparisons were considered, which comprised 6 European and 4 Asian population samples. Metaanalysis of FCGR3A polymorphism revealed a significant associa- tion between the VV genotype and the risk of developing RA relative to the VF+FF genotype (OR 1.256, 95% CI 1.045–1.510, p = 0.015), with no evidence of between-study heterogeneity (p = 0.167). In subjects of European descent, a stronger association was observed between the VV geno- type and RA than for the FF genotype (OR 1.374, 95% CI 1.101–1.714, p = 0.005). In Asians, no such association was found. Metaanalysis of the VV vs FF genotype revealed a significantly increased OR in Europeans (OR 1.399, 95% CI 1.107–1.769, p = 0.005), but not in Asians. No asso- ciation was found between RA and the FCGR2A and FCGR3B polymorphisms in all subjects and in European and Asian populations, except for the NA22 vs NA11 of FCGR3B in Europeans. Conclusion. No relation was found between the FCGR2A polymorphism and susceptibility to RA in Europeans or Asians. The FCGR3A polymorphism was found to be associated with RA in Europeans but not in Asians.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Single-Cell RNA Sequencing of Tocilizumab-Treated Peripheral Blood Mononuclear Cells As an in Vitro Model of Inflammation
    UCSF UC San Francisco Previously Published Works Title Single-Cell RNA Sequencing of Tocilizumab-Treated Peripheral Blood Mononuclear Cells as an in vitro Model of Inflammation. Permalink https://escholarship.org/uc/item/8q84n3jb Authors Zarinsefat, Arya Hartoularos, George Rychkov, Dmitry et al. Publication Date 2020 DOI 10.3389/fgene.2020.610682 Peer reviewed eScholarship.org Powered by the California Digital Library University of California fgene-11-610682 December 19, 2020 Time: 19:44 # 1 BRIEF RESEARCH REPORT published: 05 January 2021 doi: 10.3389/fgene.2020.610682 Single-Cell RNA Sequencing of Tocilizumab-Treated Peripheral Blood Mononuclear Cells as an in vitro Model of Inflammation Arya Zarinsefat1*, George Hartoularos2, Dmitry Rychkov1, Priyanka Rashmi1, Sindhu Chandran3, Flavio Vincenti1, Chun J. Yee2 and Minnie M. Sarwal1 1 Department of Surgery, University of California, San Francisco, San Francisco, CA, United States, 2 Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, United States, 3 Department of Medicine, University of California, San Francisco, San Francisco, CA, United States COVID-19 has posed a significant threat to global health. Early data has revealed that IL-6, a key regulatory cytokine, plays an important role in the cytokine storm of COVID-19. Multiple trials are therefore looking at the effects of Tocilizumab, an IL-6 receptor antibody that inhibits IL-6 activity, on treatment of COVID-19, with promising findings. As part of a clinical trial looking at the effects of Tocilizumab treatment on Edited by: kidney transplant recipients with subclinical rejection, we performed single-cell RNA Gabriele Bucci, sequencing of comparing stimulated PBMCs before and after Tocilizumab treatment.
    [Show full text]
  • CD29 Identifies IFN-Γ–Producing Human CD8+ T Cells With
    + CD29 identifies IFN-γ–producing human CD8 T cells with an increased cytotoxic potential Benoît P. Nicoleta,b, Aurélie Guislaina,b, Floris P. J. van Alphenc, Raquel Gomez-Eerlandd, Ton N. M. Schumacherd, Maartje van den Biggelaarc,e, and Monika C. Wolkersa,b,1 aDepartment of Hematopoiesis, Sanquin Research, 1066 CX Amsterdam, The Netherlands; bLandsteiner Laboratory, Oncode Institute, Amsterdam University Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands; cDepartment of Research Facilities, Sanquin Research, 1066 CX Amsterdam, The Netherlands; dDivision of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands; and eDepartment of Molecular and Cellular Haemostasis, Sanquin Research, 1066 CX Amsterdam, The Netherlands Edited by Anjana Rao, La Jolla Institute for Allergy and Immunology, La Jolla, CA, and approved February 12, 2020 (received for review August 12, 2019) Cytotoxic CD8+ T cells can effectively kill target cells by producing therefore developed a protocol that allowed for efficient iso- cytokines, chemokines, and granzymes. Expression of these effector lation of RNA and protein from fluorescence-activated cell molecules is however highly divergent, and tools that identify and sorting (FACS)-sorted fixed T cells after intracellular cytokine + preselect CD8 T cells with a cytotoxic expression profile are lacking. staining. With this top-down approach, we performed an un- + Human CD8 T cells can be divided into IFN-γ– and IL-2–producing biased RNA-sequencing (RNA-seq) and mass spectrometry cells. Unbiased transcriptomics and proteomics analysis on cytokine- γ– – + + (MS) analyses on IFN- and IL-2 producing primary human producing fixed CD8 T cells revealed that IL-2 cells produce helper + + + CD8 Tcells.
    [Show full text]
  • Human Fcgr2a / Cd32a (H131) Protein Catalog # AMS.CD1-H5223-100UG for Research Use Only
    Human FcGR2A / CD32a (H131) Protein Catalog # AMS.CD1-H5223-100UG For Research Use Only Description Source Human FcGR2A / CD32a (H131) Protein,also called Human FcGR2A / CD32a Protein (167 His), Ala 36 - Ile 218 (Accession # P12318-1), was produced in human 293 cells (HEK293) Predicted N-terminus Ala 36 Protein Structure Molecular Human FcGR2A / CD32a (H131), His Tag is fused with a polyhistidine tag at the C-terminus, and has a calculated MW of 21.1 Characterization kDa. The predicted N-terminus is Ala 36. The reducing (R) protein migrates as 29-32 kDa in SDS-PAGE due to glycosylation. Endotoxin Less than 1.0 EU per μg by the LAL method. >95% as determined by SDS-PAGE. Purity Bioactivity The bioactivity is measured by its binding ability to Ipilimumab in a SPR assay. Immobilized Human FcGR2A / CD32a (H131), His Tag (Cat# AMS.CD1-H5223-100UG) can bind Ipilimumab with affinity constant of around 2.7 uM. Measured by its binding ability in a functional ELISA. Immobilized human IgG4 at 10μg/mL (100 µl/well),can bind Human FcGR2A / CD32a (H131), His Tag (Cat# AMS.CD1-H5223-100UG) with a linear of 0.1-2 μg/mL. Formulation and Storage Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation. Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the Reconstitution reconstitution protocol provided in the COA. Storage For long term storage, the product should be stored at lyophilized state at -20°C or lower.
    [Show full text]